Among the cancers that resist every standard weapon medicine offers, head and neck tumours have long represented a particular kind of despair — a narrowing corridor with no visible door. A clinical trial conducted across 55 hospitals in 11 countries has now reported that a bispecific antibody called amivantamab shrank tumours in 42% of patients who had exhausted chemotherapy and immunotherapy, eliminating disease entirely in 15 cases. The finding, emerging from London's Institute of Cancer Research, suggests that simultaneously blocking two cancer growth pathways while reawakening the immune s
Evening Standard
· May 30, 2026
· health
· 3 min read
High
Sourcing: Verified
Cancer injection destroys resistant tumours in breakthrough trial
Patients with treatment-resistant head and neck cancer experienced significant symptom relief including reduced pain, swelling, and improved quality of life compared to chemotherapy side effects.
◉
Health & Medicine
8293 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Patient's persistence leads to rare kidney disease diagnosis and break…
CBS News · 99% match
Experimental pancreatic cancer drug shows survival promise in clinical…
Google News · 99% match
Ebola outbreak in Congo reaches 750 cases with no approved treatment a…
Devdiscourse · 99% match
Rare Bundibugyo Ebola strain spreads undetected in Congo, triggering g…
ThePrint · 99% match
Related Coverage
7NEWS · Aug 23
Model's Foot Cut Led to Heart Surgery, Baby Loss—Now Advocating for Better Diagnostics
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Bias & Framing
⚖
Article presents cancer treatment trial results with optimistic framing and expert endorsement, lacking critical perspective on limitations, side effects, or comparative efficacy data.
Bias Direction
center-right
Confidence
MED
Breakthrough narrative with emphasis on unprecedented success and expert validation. Uses patient testimonial to humanize positive outcomes. Minimizes discussion of trial limitations, sample size context, or long-term efficacy questions.
unprecedentedly strong responses
eradicated entire tumours
breakthrough trial
very striking
potential to benefit many thousands
Oncologists or researchers not involved in the trial offering independent assessment
Discussion of trial phase limitations (appears to be Phase 2, not Phase 3)
Comparative efficacy data against existing treatments
Detailed adverse event profile or long-term safety data
Cost/accessibility considerations for patients
Realistic timeline for drug approval and availability
Perspectives from patient advocacy groups on unmet needs
Geopolitical Impact
🌎
Cancer treatment breakthrough has minimal geopolitical implications; primarily a medical advancement affecting healthcare access and pharmaceutical competition globally.
Escalation Risk
low
Confidence
HIGH
United Kingdom
European Union
United States
Global healthcare markets
Johnson & Johnson strengthens market position in oncology; UK's Institute of Cancer Research enhances scientific soft power; potential shift in treatment accessibility favoring developed nations with advanced healthcare infrastructure.
Economic Lens
📈
Breakthrough cancer treatment amivantamab shows 42% tumor shrinkage in resistant cases, potentially creating significant pharmaceutical market opportunity and reducing healthcare costs through improved outcomes.
Market Signal
bullish
Confidence
MED
Pharmaceutical and biotechnology
Healthcare and medical devices
Hospital and clinical services
Health insurance and NHS budgets
Patients gain access to effective treatment option for previously untreatable cancers, reducing suffering and improving quality of life. Potential reduction in long-term healthcare costs and lost productivity from cancer treatment. Improved outcomes may increase demand for cancer screening and early detection services.
Likely accelerated regulatory approval pathways (NICE evaluation, FDA fast-track consideration). Potential NHS budget reallocation toward oncology. Pricing negotiations between Johnson & Johnson and healthcare systems. Possible expansion of cancer treatment access programs. May influence future R&D investment in immunotherapy combinations.